Ineffective behavioral rescue despite partial brain Dp427 restoration by AAV9-U7-mediated exon 51 skipping in mdx52 mice
Abstract
The mdx52 mouse model exhibits a common mutation profile associated with brain involvement in Duchenne muscular dystrophy (DMD), characterized by heightened anxiety, fearfulness, and impaired associative fear learning. Deletion of exon 52 disrupts the expression of two dystrophins found in the brain (Dp427 and Dp140), and is eligible for therapeutic exon-skipping strategies. We previously demonstrated that a single intracerebroventricular administration of an antisense oligonucleotide (ASO) targeting exon 51 of the Dmd gene could restore 5% to 15% of Dp427 expression. This treatment reduced anxiety and unconditioned fear in mdx52 mice, improved fear conditioning acquisition, and partially improved fear memory tested 24 hours later. To improve the restoration of Dp427 and induce a long-lasting therapeutic effect, we employed a vectorized approach using an AAV-U7snRNA vector to deliver antisense sequences to the brains of mdx52 mice. We evaluated two AAV serotypes known for their brain transduction efficiency (AAV9 and RH10) and two delivery routes, intracisterna magna and intracerebroventricular (ICV) injections, to maximize brain targeting. Based on GFP expression data, we selected the AAV9 capsid and a bilateral ICV delivery route. Using this approach, we demonstrated that ICV administration of AAV9-U7-Ex51M induced exon 51 skipping and restored Dp427 expression in the brains of adult mdx52 mice, though with significant variability among individuals. While a few mice showed high Dp427 expression levels, the average restoration was limited to approximately 6% to 12%. In conclusion, inducing exon skipping in the brains of adult mdx52 mice using the vectorized AAV9-U7 approach was less effective than synthetic ASO treatment and did not improve the emotional behavior of mdx52 mice.
Related
- Spatial Lipidomics and Transcriptomics Reveal Nicotine-Mediated Restoration of Lipid Homeostasis in Parkinson’s Disease
- Rezpegaldesleukin and Regulatory T Cell Restoration in Immune-Mediated Skin Diseases
- Drp1 in M1 layer V GABAergic neurons orchestrates rTMS-mediated motor restoration and analgesia after spinal cord injury
- Pharmacological Role of 3-O-Methyldopa in the Central Nervous System-Mediated Behavioral Effects of L-DOPA in Rats
- Effect of a combined woolwich massage, acupressure, and Breastfeeding Exclusive Self Training (BEST) for moms e-book intervention on ineffective breastfeeding: A case study
BibTeX
@article{vacca2026ineffective,
title = {{Ineffective behavioral rescue despite partial brain Dp427 restoration by AAV9-U7-mediated exon 51 skipping in mdx52 mice}},
author = {Ophélie Vacca and Amel Saoudi and Mathilde Doisy and Xaysongkhame Phongsavanh and Olivier Le Coz and Cathy Nagy and Julia Kuzniar and Cyrille Vaillend and Aurélie Goyenvalle},
journal = {Molecular Therapy - Nucleic Acids},
year = {2026},
month = nov,
doi = {10.1016/j.omtn.2025.102779},
url = {https://hal.science/hal-05851892v1},
note = {CC BY},
}
RIS
TY - JOUR
TI - Ineffective behavioral rescue despite partial brain Dp427 restoration by AAV9-U7-mediated exon 51 skipping in mdx52 mice
AU - Ophélie Vacca
AU - Amel Saoudi
AU - Mathilde Doisy
AU - Xaysongkhame Phongsavanh
AU - Olivier Le Coz
AU - Cathy Nagy
AU - Julia Kuzniar
AU - Cyrille Vaillend
AU - Aurélie Goyenvalle
PY - 2026
DA - 2026/11/04
JO - Molecular Therapy - Nucleic Acids
DO - 10.1016/j.omtn.2025.102779
UR - https://hal.science/hal-05851892v1
AB - The mdx52 mouse model exhibits a common mutation profile associated with brain involvement in Duchenne muscular dystrophy (DMD), characterized by heightened anxiety, fearfulness, and impaired associative fear learning. Deletion of exon 52 disrupts the expression of two dystrophins found in the brain (Dp427 and Dp140), and is eligible for therapeutic exon-skipping strategies. We previously demonstrated that a single intracerebroventricular administration of an antisense oligonucleotide (ASO) targeting exon 51 of the Dmd gene could restore 5% to 15% of Dp427 expression. This treatment reduced anxiety and unconditioned fear in mdx52 mice, improved fear conditioning acquisition, and partially improved fear memory tested 24 hours later. To improve the restoration of Dp427 and induce a long-lasting therapeutic effect, we employed a vectorized approach using an AAV-U7snRNA vector to deliver antisense sequences to the brains of mdx52 mice. We evaluated two AAV serotypes known for their brain transduction efficiency (AAV9 and RH10) and two delivery routes, intracisterna magna and intracerebroventricular (ICV) injections, to maximize brain targeting. Based on GFP expression data, we selected the AAV9 capsid and a bilateral ICV delivery route. Using this approach, we demonstrated that ICV administration of AAV9-U7-Ex51M induced exon 51 skipping and restored Dp427 expression in the brains of adult mdx52 mice, though with significant variability among individuals. While a few mice showed high Dp427 expression levels, the average restoration was limited to approximately 6% to 12%. In conclusion, inducing exon skipping in the brains of adult mdx52 mice using the vectorized AAV9-U7 approach was less effective than synthetic ASO treatment and did not improve the emotional behavior of mdx52 mice.
SN - 2162-2531
ER -